Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24.357
Filtrar
1.
BMC Infect Dis ; 24(1): 1087, 2024 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-39354416

RESUMEN

BACKGROUND: Drug-resistant tuberculosis (DR-TB) remains a threat to public health. Shorter regimens have been proposed as potentially valuable treatments for multidrug or rifampicin resistant tuberculosis (MDR/RR-TB). We undertook a systematic review and network meta-analysis to evaluate the efficacy and safety of shorter MDR/RR-TB regimens. METHODS: We searched PubMed/MEDLINE, Cochrane Center for Clinical Trials (CENTRAL), Scopus, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, US Food and Drug Administration, and Chinese Clinical Trial Registry for primary articles published from 2013 to July 2023. Favorable (cured and treatment completed) and unfavorable (treatment failure, death, loss to follow-up, and culture conversion) outcomes were assessed as the main efficacy outcomes, while adverse events were assessed as the safety outcomes. The network meta-analysis was performed using R Studio version 4.3.1 and the Netmeta package. The study protocol adhered to the PRISMA-NMA guidelines and was registered in PROSPERO (CRD42023434050). RESULT: We included 11 eligible studies (4 randomized control trials and 7 cohorts) that enrolled 3,548 patients with MDR/RR-TB. Treatment with a 6-month combination of BdqLzdLfxZTrd/Eto/H had two times more favorable outcomes [RR 2.2 (95% CI 1.22, 4.13), P = 0.0094], followed by a 9-11 month combination of km/CmMfx/LfxPtoCfzZEHh [RR1.67 (95% CI 1.45, 1.92), P < 0.001] and a 6-month BdqPaLzdMfx [RR 1.64 (95% CI 1.24, 2.16), P < 0.0005] compared to the standard longer regimens. Treatment with 6 months of BdqPaLzdMfx [RR 0.33 (95% CI 0.2, 0.55), P < 0.0001] had a low risk of severe adverse events, followed by 6 months of BdqPaLzd [RR 0.36 (95% CI 0.22, 0.59), P ≤ 0.001] and BdqPaLzdCfz [RR 0.54 (95% CI 0.37, 0.80), P < 0.0001] than standard of care. CONCLUSION: Treatment of patients with RR/MDR-TB using shorter regimens of 6 months BdqLzdLfxZTrd/Eto/H, 9-11 months km/CmMfx/LfxPtoCfzZEHh, and 6 months BdqPaLzdMfx provides significantly higher cure and treatment completion rates compared to the standard longer MDR/RR-TB. However, 6BdqPaLzdMfx, 6BdqPaLzd, and 6BdqPaLzdCfz short regimens are significantly associated with decreased severity of adverse events. The findings are in support of the current WHO-recommended 6-month shorter regimens.


Asunto(s)
Antituberculosos , Metaanálisis en Red , Rifampin , Tuberculosis Resistente a Múltiples Medicamentos , Humanos , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Rifampin/uso terapéutico , Antituberculosos/uso terapéutico , Antituberculosos/efectos adversos , Resultado del Tratamiento , Mycobacterium tuberculosis/efectos de los fármacos
2.
JNMA J Nepal Med Assoc ; 62(271): 220-222, 2024 Feb 29.
Artículo en Inglés | MEDLINE | ID: mdl-39356780

RESUMEN

ABSTRACT: The mediastinum, located between the pleural sacs, has three compartments. The anterior mediastinum spans anteriorly from the sternum to the pericardium and brachiocephalic vessels posteriorly. Common lesions in this area include thymomas, lymphomas, teratomatous neoplasms, and thyroid masses. A mediastinal mass in the setting of tuberculous meningoencephalitis is an uncommon presentation of tuberculosis. We present a case of a 20-year-old girl with fever and headache diagnosed with tuberculous meningoencephalitis. A thorough workup revealed an anterior mediastinal mass, histopathologically diagnosed as tubercular in origin. Treatment involved surgery and antituberculosis therapy. Tuberculosis can manifest uniquely, and an isolated mediastinal mass, especially in an immunocompetent individual, is unusual. Treatment typically involves a combination of antimicrobial medications, and in some cases, surgical intervention may be necessary to address complications or persistent masses. This case emphasizes the importance of considering tuberculosis as a diagnosis when a patient presents with a mass in the anterior mediastinum.


Asunto(s)
Antituberculosos , Humanos , Femenino , Antituberculosos/uso terapéutico , Adulto Joven , Tuberculosis Meníngea/diagnóstico , Tuberculosis Meníngea/tratamiento farmacológico , Tomografía Computarizada por Rayos X/métodos , Diagnóstico Diferencial
3.
JNMA J Nepal Med Assoc ; 62(272): 275-278, 2024 Mar 31.
Artículo en Inglés | MEDLINE | ID: mdl-39356849

RESUMEN

In Southeast Asia, the higher prevalence of Intestinal tuberculosis (TB) challenges the diagnosis of Crohn's disease (CD) due to their overlapping symptoms. This case involves a 25-year-old male misdiagnosed with Intestinal tuberculosis presenting with abdominal pain, weight loss, and bowel ulceration. Recurrence after anti-tubercular therapy led to further investigation paving to right hemicolectomy and histopathological analysis confirming Crohn's disease. This case highlights the complexity of the diagnosis of Crohn's disease in tuberculosis-prevalent areas, stressing the clinical importance, advanced diagnostics tools, and multidisciplinary approach for effective intervention.


Asunto(s)
Enfermedad de Crohn , Tuberculosis Gastrointestinal , Humanos , Masculino , Tuberculosis Gastrointestinal/diagnóstico , Tuberculosis Gastrointestinal/complicaciones , Enfermedad de Crohn/complicaciones , Enfermedad de Crohn/diagnóstico , Adulto , Errores Diagnósticos , Colectomía/métodos , Antituberculosos/uso terapéutico , Enfermedades del Ciego/diagnóstico , Enfermedades del Ciego/complicaciones
5.
Clin Lab ; 70(10)2024 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-39382920

RESUMEN

BACKGROUND: Tuberculous pleurisy (TP) is one of the most common types of extrapulmonary tuberculosis, often secondary to tuberculosis (TB). Clinical and imaging manifestations of non-tuberculous mycobacterial pulmonary diseases (NTM-PD) are usually similar to those of tuberculosis. Because of their similarity and the high incidence of tuberculosis, non-tuberculous mycobacterial infections are often overlooked for a long time. Especially in people without immunodeficiency. METHODS: Mycobacterium tuberculosis (MTB) in pleural effusion was found by metagenomic next-generation sequencing (mNGS). During anti-tuberculosis treatment, mNGS of lung tissue by ultrasound-guided percutaneous lung puncture revealed that this patient had combined NTM-PD. RESULTS: Mycobacterium chelonae (M. chelonae) was detected by mNGS, and after anti-NTM treatment, the patient's chest CT showed that the inflammation was absorbed more than before, and the patient's symptoms improved. CONCLUSIONS: When TB is poorly treated with standardized anti-tuberculosis therapy, comorbid non-tuberculous mycobacterial infections may be considered, and mNGS may complement traditional pathogenetic testing.


Asunto(s)
Infecciones por Mycobacterium no Tuberculosas , Mycobacterium tuberculosis , Derrame Pleural , Humanos , Infecciones por Mycobacterium no Tuberculosas/diagnóstico , Infecciones por Mycobacterium no Tuberculosas/microbiología , Mycobacterium tuberculosis/aislamiento & purificación , Mycobacterium tuberculosis/genética , Derrame Pleural/microbiología , Derrame Pleural/diagnóstico , Masculino , Secuenciación de Nucleótidos de Alto Rendimiento , Antituberculosos/uso terapéutico , Persona de Mediana Edad , Femenino , Tomografía Computarizada por Rayos X/métodos , Tuberculosis Pleural/diagnóstico , Tuberculosis Pleural/microbiología , Tuberculosis Pleural/tratamiento farmacológico
7.
BMC Infect Dis ; 24(1): 1110, 2024 Oct 07.
Artículo en Inglés | MEDLINE | ID: mdl-39375585

RESUMEN

BACKGROUND: The reactivation of tuberculosis (TB) among kidney transplant (KT) recipients in an endemic area is of general concern. However, the epidemiology of latent TB infection (LTBI) status and its dynamic change responses have not been explored. METHODS: Between September 2020 and August 2021, a prospective study was conducted to investigate the status of LTBI in KT recipients who received a 9-month isoniazid universal prophylaxis. This status was measured using the interferon-gamma release assay (IGRA) with T-SPOT.TB before transplant, as well as at one month and nine months post-transplant. RESULTS: Ninety-one KT recipients had a mean (SD) age of 45 (11) years, and 41% were female. Sixty-eight (75%) patients received a deceased donor allograft, and eighty-six (91%) patients received induction immunosuppressive therapy. The IGRA results were positive, borderline, negative, and indeterminate in 14 (15.4%), 6 (6.6%), 64 (70.3%), and 7 (7.8%) patients, respectively. Among 84 evaluable patients, 20 (23.8%) KT recipients were defined as having LTBI. Older age was significantly associated with LTBI (OR 1.06 [95% CI 1.01-1.12], p = 0.03). Among the 77 KT recipients who completed monitoring, 55 had negative IGRA results. Three (5.4%) KT recipients had conversion post-transplant. One of them developed pulmonary TB at 1 week after the transplant. Among the 13 patients with positive results, 8 (61.5%) remained positive, 1 (7.7%) had an indeterminate result at 1-month post-transplant and subsequently tested positive at 9 months post-transplant, and 4 (30.8%) experienced reversion to negative results throughout the study. CONCLUSIONS: In a high TB-endemic area, one-quarter of KT recipients were reported to have LTBI, and the dynamic change of IGRA response in KT recipients is plausible post-transplant.


Asunto(s)
Ensayos de Liberación de Interferón gamma , Trasplante de Riñón , Tuberculosis Latente , Receptores de Trasplantes , Humanos , Tuberculosis Latente/diagnóstico , Femenino , Trasplante de Riñón/efectos adversos , Masculino , Persona de Mediana Edad , Ensayos de Liberación de Interferón gamma/métodos , Estudios Prospectivos , Adulto , Isoniazida/uso terapéutico , Antituberculosos/uso terapéutico , Tamizaje Masivo/métodos
8.
BMC Infect Dis ; 24(1): 1112, 2024 Oct 07.
Artículo en Inglés | MEDLINE | ID: mdl-39375590

RESUMEN

BACKGROUND: Drug resistance (DR) is one of the several challenges to global tuberculosis (TB) control. The implementation of bedaquiline (BED) for DR-TB after more than 40 years was expected to improve treatment outcomes as well as microbiologic conversion and adverse events (AE) occurrence. METHODS: Retrospective cohort study based on secondary data of patients with rifampicin-resistant (RR) or multidrug-resistant (MDR) TB reported to the Outpatient Clinic of Mycobacterial Diseases of the Thorax Diseases Institute - Federal University of Rio de Janeiro - Brazil, between 2016 and 2023. We aimed to evaluate microbiologic conversion, AE and TB treatment outcomes and compare them according to the treatment regimen used for RR/MDR-TB patients under routine conditions [Injectable Containing Regimens (ICR) versus BED Containing Regimens (BCR)]. Logistic regression and survival analysis using Cox regression and Kaplan Meier curve were used for statistical analysis. RESULTS: Of the 463 DR-TB patients notified during the study period, 297 (64.1%) were included for analysis (ICR = 197 and BCR = 100). Overall AEs were more frequent (83.7 vs. 16.3%, p < 0.001) and occurred earlier in the ICR group (15 days vs. 65 days, p = 0.003). There were no cases of cardiotoxicity requiring interruption of BED treatment. None of the regimens of treatment tested were associated with smear or culture conversion on Cox regression analysis (p = 0.60 and 0.88, respectively). BED-containing regimens were also associated with favorable outcomes in multivariable logistic regression [adjusted odds ratio (aOR) = 2.63, 95% confidence interval (CI)1.36-5.07, p = 0.004], as higher years of schooling, primary drug resistance, and no previous TB treatment. In the survival analysis, BCR was inversely associated with the occurrence of AE during treatment follow-up (aHR 0.24, 95% CI 0.14-0.41, p < 0.001). In addition, TB treatment regimens with BED were also associated with favorable outcomes (aHR 2.41, 95% CI 1.62-3.57, p < 0.001), along with no illicit drug use and primary drug resistance. CONCLUSIONS: The implementation of a fully oral treatment for RR/MDR-TB in a reference center in Brazil was safe and associated with favorable outcomes under routine conditions, despite social, demographic, and behavioral factors that may influence TB treatment completion.


Asunto(s)
Antituberculosos , Diarilquinolinas , Rifampin , Tuberculosis Resistente a Múltiples Medicamentos , Humanos , Estudios Retrospectivos , Brasil , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Femenino , Diarilquinolinas/uso terapéutico , Diarilquinolinas/administración & dosificación , Diarilquinolinas/efectos adversos , Masculino , Rifampin/uso terapéutico , Antituberculosos/uso terapéutico , Antituberculosos/efectos adversos , Antituberculosos/administración & dosificación , Adulto , Persona de Mediana Edad , Resultado del Tratamiento , Adulto Joven , Mycobacterium tuberculosis/efectos de los fármacos , Inyecciones
9.
PLoS One ; 19(10): e0311408, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39361576

RESUMEN

BACKGROUND: Ethiopia faces a significant burden of Tuberculosis (TB), being one of the high-burden countries, and the emergence of the Coronavirus Disease 2019 (COVID-19) has become a dominant health concern, particularly in resource-limited settings. The repercussions of COVID-19 on TB care are evident, leading to a surge in undiagnosed TB cases, challenges in medication adherence, and an escalation of drug resistance. Consequently, a thorough assessment of the impact of COVID-19 on TB care becomes imperative to devise a tailored program for managing TB amidst future pandemics, natural disasters, and conflict crises. METHODS: A mixed-methods study design was utilized, encompassing a randomly selected 10 health centers (HCs) and 3 hospitals among government owned 98 HCs and 5 hospitals in Addis Ababa, Ethiopia. All TB patients who were on follow-up during the study period were included. The study period was from March 4, 2020, to December 4, 2020, with the corresponding period of March 4, 2019, to December 4, 2019, serving as the baseline for comparison. Quantitative data were gathered from TB patients' medical registries, laboratory registries, and treatment follow-up charts. Complementary qualitative data were acquired through in-depth interviews. Both qualitative and quantitative data were collected from January 17, 2022 to May 13, 2022. RESULTS: Following the onset of the pandemic, there was a notable and statistically significant decline in both the detection of TB cases and the number of positive results across all study sites. Bacteriological TB tests reduced from 5837 to 2126 patients, and TB-positive cases decreased from 500 to 218, representing declines of 63.6% and 56.4%, respectively. The overall number of TB patients undergoing treatment also experienced a decrease from 1431 to 1051, marking a 26.6% reduction. Additionally, there was a 10% increase in the proportion of extra-pulmonary TB cases. The impact of the pandemic extended to TB treatment outcomes, with adverse effects on cure rates, death rates, loss of follow-up, and medication adherence. The apprehension of contracting COVID-19 and the implementation of isolation measures contributed to a decline in healthcare-seeking behaviors among patients, fostering negative perceptions and practices among healthcare workers. The challenges further exacerbated due to a shortage of personal protective equipment, a lack of rapid diagnostic test tools, clinical presentations resembling COVID-19, and a shift in government policies. These factors collectively posed significant obstacles to effective TB care during the pandemic. CONCLUSION: The profound impact of COVID-19 on critical TB care service indicators, including TB detection, treatment initiation, and treatment outcomes, underscores the need for immediate and collaborative measures. It is imperative to implement strategies that ensure the resumption of all TB care services concurrently with efforts to control COVID-19. A comprehensive and coordinated approach is essential to mitigate the adverse effects of the pandemic on TB management and safeguard public health.


Asunto(s)
COVID-19 , Instituciones de Salud , Tuberculosis , Humanos , Etiopía/epidemiología , COVID-19/epidemiología , COVID-19/diagnóstico , Femenino , Masculino , Adulto , Tuberculosis/diagnóstico , Tuberculosis/epidemiología , Tuberculosis/tratamiento farmacológico , Persona de Mediana Edad , Adolescente , Adulto Joven , SARS-CoV-2/aislamiento & purificación , Antituberculosos/uso terapéutico , Niño , Anciano
10.
J Assoc Physicians India ; 72(10): 101-103, 2024 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-39390873

RESUMEN

India contributes to 26% of the global tuberculosis (TB) burden, with very high mortality and morbidity. The exact incidence of disseminated TB cannot be established among the general population but accounts for <2% of cases among immunocompromised hosts and constitutes 20% of all extrapulmonary TB cases. Disseminated TB has a very high mortality rate of around 25-30%. Miliary TB, a disseminated form, is another entity of TB that poses a health burden due to its difficulty in diagnosis. This entity usually presents with subclinical symptoms and poses a diagnostic challenge in the absence of specific diagnostic tests. We present a case of a young female with epistaxis and thrombocytopenia who was diagnosed with disseminated TB [miliary, bone cyst, bone marrow (BM) involvement].


Asunto(s)
Tuberculosis Miliar , Humanos , Femenino , Tuberculosis Miliar/diagnóstico , Tuberculosis Miliar/tratamiento farmacológico , Adulto , Antituberculosos/uso terapéutico , Trombocitopenia/etiología , Trombocitopenia/diagnóstico , Epistaxis/etiología , Quistes Óseos/diagnóstico
12.
Indian J Tuberc ; 71 Suppl 2: S184-S190, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39370181

RESUMEN

BACKGROUND: Tuberculosis is still a major public health concern that affects millions of people worldwide. Despite the fact that tuberculosis has a well-established treatment, little attention is paid to the quality of life of TB patients on treatment. Poor quality of life has been linked to lower treatment adherence in patients having TB. As a result, the purpose of this study was to evaluate the quality of life of tuberculosis patients and its associated factors. METHODS: The study was a cross-sectional study conducted in Southwest Nigeria among drug-susceptible tuberculosis patients between February and September 2020. The World Health Organization Quality of Life Brief version questionnaire was used to collect data on quality of life (WHOQOL-BREF). A total of 330 people were approached. SPSS version 20 was used to analyze the data. The descriptive data was analyzed using means, standard deviations, and proportions, while the Chi-Square test and binary logistic regression were used to assess the association between variables. P < 0.05 was used to determine statistical significance. RESULTS: The respondents' average age was 35.50 ± 11.59 years and most of the respondents (67.9%) were males. The overall mean quality of life was good (4.01 ± 0.529) with the highest score (66.47 ± 10.50) in the environmental domain and the least score (62.88 ± 15.36) in the social domain. There was an association between good quality of life and the patient's length of illness prior to diagnosis (AOR = 0.468, 95% CI = 0.225-0.973). CONCLUSION: In line with this study, the overall quality of life of drug-susceptible tuberculosis patients is good and is related to the duration of illness before the diagnosis of tuberculosis was made. Therefore, more efforts should be made to increase awareness of tuberculosis and intensify active case finding to enhance early case detection and a better quality of life.


Asunto(s)
Calidad de Vida , Tuberculosis , Humanos , Nigeria , Masculino , Femenino , Adulto , Estudios Transversales , Persona de Mediana Edad , Tuberculosis/tratamiento farmacológico , Tuberculosis/psicología , Antituberculosos/uso terapéutico , Adulto Joven , Encuestas y Cuestionarios , Cumplimiento de la Medicación/estadística & datos numéricos , Cumplimiento de la Medicación/psicología
13.
Indian J Tuberc ; 71 Suppl 2: S191-S196, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39370182

RESUMEN

BACKGROUND: Health is a state of health, both physically, mentally, spiritually, and socially that allows everyone to live a productive life socially and economically. Pulmonary tuberculosis is a global health problem that could impact on productivity and quality of life. The number of TB cases in Indonesia According to WHO, there are an estimated 1,020,000 new TB cases per year (399 per 100,000 population) with 100,000 deaths per year (41 per 100,000 population). Pulmonary tuberculosis is a global health problem that can impact productivity and quality of life. The persistence of family support in improving the compliance of pulmonary tuberculosis patients in taking medication is the key to the success of tuberculosis treatment. AIMS: This study aims to determine the involvement of religious organizations in supporting tuberculosis patients to improve treatment adherence. METHODS: This research is a qualitative study with a phenomenological approach. Data were collected using in-depth interviews and then analyzed by content analysis. The informants in this study consisted of 8 participants. RESULT: The results of this study found three themes, namely Understanding TB treatment, Socialinteraction management, and Socialsupport. CONCLUSIONS: It was concluded that the support of religious organizations during the patient's treatment can increase the patient's compliance to take medicine regularly and make regular controls/visits. It is also recommended that families encourage patients to continue to participate in religious activities while still complying with health procedures.


Asunto(s)
Antituberculosos , Cumplimiento de la Medicación , Tuberculosis Pulmonar , Humanos , Cumplimiento de la Medicación/estadística & datos numéricos , Cumplimiento de la Medicación/psicología , Tuberculosis Pulmonar/tratamiento farmacológico , Masculino , Femenino , Adulto , Indonesia , Antituberculosos/uso terapéutico , Investigación Cualitativa , Apoyo Social , Persona de Mediana Edad , Organizaciones Religiosas , Calidad de Vida
14.
Indian J Tuberc ; 71 Suppl 2: S178-S183, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39370180

RESUMEN

BACKGROUND: Undernutrition is a risk factor for developing tuberculosis (TB) and adherence to treatment leads to successful treatment outcomes. OBJECTIVES: To assess the nutritional status and adherence to treatment among tuberculosis patients in Bhatar Community Development Block of Purba Bardhaman district, West Bengal, India. MATERIAL & METHODS: A cross sectional descriptive study was conducted among all the 82 tuberculosis patients registered between April to June, 2021, under NTEP in Bhatar tuberculosis unit (TU), who completed at least 1 month of therapy. Nutritional status was assessed based on BMI and adherence to treatment was evaluated by interviewing with a validated version of Morisky Medication Adherence Scale (MMAS-8-Item). Data was analysed using SPSS v23. RESULTS: Among the 82 subjects, 51 (62.2%) were found to be underweight and overall high level of adherence to treatment was found among 51 (62.2%) of study subjects. Subjects aged >45 years (AOR 3.686, 95% CI: 1.147-11.842) and having extra-pulmonary Tuberculosis (AOR 8.539, 95% CI: 1.305-55.871) were significantly associated as being adherent to treatment. CONCLUSION: Health education, awareness and more vigilant monitoring is still needed so that TB patients can be cured successfully. Special attention needs to be given on the nutritional status of the TB patients.


Asunto(s)
Antituberculosos , Cumplimiento de la Medicación , Estado Nutricional , Tuberculosis , Humanos , India/epidemiología , Masculino , Femenino , Antituberculosos/uso terapéutico , Estudios Transversales , Adulto , Persona de Mediana Edad , Cumplimiento de la Medicación/estadística & datos numéricos , Tuberculosis/tratamiento farmacológico , Tuberculosis/epidemiología , Delgadez/epidemiología , Tuberculosis Pulmonar/tratamiento farmacológico , Tuberculosis Pulmonar/epidemiología , Adulto Joven , Desnutrición/epidemiología , Índice de Masa Corporal , Adolescente
15.
Indian J Tuberc ; 71 Suppl 2: S208-S213, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39370185

RESUMEN

BACKGROUND: Tuberculosis (TB) is a global health concern, impacting millions annually, with limited attention to the psychological distress it inflicts. Psychological comorbidities, such as depression, anxiety, and stress, significantly affect the quality of life (QoL) of TB patients. Available literature on this topic is restricted to the pulmonary TB (PTB) patients; while psychological issues of the extrapulmonary TB (EPTB) patients who comprise a significant proportion of this disease entity remains unexplored. Additionally, the impact of anti-TB treatment on psychological parameters has received limited attention and vice-versa. This study aimed to assess depression, anxiety, stress, and QoL of TB patients at diagnosis and to understand how these parameters change after the intensive phase of treatment. METHODS: A longitudinal observational study involving 40 TB patients (31 EPTB and 9 TB) was conducted to assess depression, anxiety, stress and QoL among them. Participants were followed up after the intensive treatment phase. RESULTS: At baseline, 32.5% (n = 13) and 65% (n = 26) participants experienced moderate-severe depression, and moderate-severe anxiety, and stress, respectively. QoL was notably compromised, especially in the psychological domain. Post-intensive treatment, anxiety and depression showed significant improvement (Z = -2.271, p = 0.023 and Z = -2.093, p = 0.036), but QoL and stress levels remained largely unchanged (p > 0.05). CONCLUSION: This study highlights the high prevalence of psychological distress and poor QoL among TB patients. Following intensive phase of therapy, severity of depression and anxiety reduced significantly; however, change in stress-level and QoL was non-significant. Although study is limited by in terms for small sample size, the need of holistic, multidisciplinary treatment approach (including mental health professionals) for such patients can't be overemphasized. Implementing baseline psychological screenings and providing mental health support if required, are critical to improve the overall health and QoL of these individuals.


Asunto(s)
Antituberculosos , Ansiedad , Depresión , Calidad de Vida , Tuberculosis Pulmonar , Humanos , Calidad de Vida/psicología , Masculino , India/epidemiología , Estudios Longitudinales , Femenino , Adulto , Tuberculosis Pulmonar/psicología , Tuberculosis Pulmonar/tratamiento farmacológico , Depresión/epidemiología , Depresión/psicología , Ansiedad/epidemiología , Ansiedad/psicología , Antituberculosos/uso terapéutico , Persona de Mediana Edad , Estrés Psicológico/epidemiología , Tuberculosis/psicología , Tuberculosis/tratamiento farmacológico , Tuberculosis/epidemiología , Adulto Joven , Tuberculosis Extrapulmonar
16.
Indian J Tuberc ; 71 Suppl 2: S214-S220, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39370186

RESUMEN

AIM: The present study aimed to compare the adherence to anti-TB treatment among post-COVID-19 pulmonary TB cases and TB patients without a history of COVID-19 in South India. METHODS: A prospective, cross sectional study was conducted in all drug-sensitive pulmonary tuberculosis patients in National TB Elimination Program. The research investigates the impact of the COVID-19 pandemic on TB management, considering both subjective and objective measures of adherence. Data were collected using a validated instrument for subjective assessment and urine metabolite testing for objective evaluation. RESULTS: The results reveal significant differences (p < 0.05) between subjective and objective adherence measures, emphasizing the need for accurate and comprehensive assessment methods. However, there is no statistically significant difference (p > 0.05) in adherence to anti-TB treatment among post-COVID-19 pulmonary TB cases and TB patients without a history of COVID-19 in South India. The reason for non-adherence in both groups were ATT side effects, loss of daily wages, forgetting to take medication and lazy to take medications. CONCLUSION: The study concluded that there is no statistically significant difference (p > 0.05) in adherence to anti-TB treatment among post-COVID-19 pulmonary TB cases and TB patients without a history of COVID-19.


Asunto(s)
Antituberculosos , COVID-19 , Cumplimiento de la Medicación , Tuberculosis Pulmonar , Humanos , COVID-19/epidemiología , India/epidemiología , Estudios Transversales , Tuberculosis Pulmonar/tratamiento farmacológico , Tuberculosis Pulmonar/epidemiología , Masculino , Femenino , Estudios Prospectivos , Adulto , Cumplimiento de la Medicación/estadística & datos numéricos , Antituberculosos/uso terapéutico , Persona de Mediana Edad , SARS-CoV-2
17.
Indian J Tuberc ; 71 Suppl 2: S229-S236, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39370189

RESUMEN

BACKGROUND: India shares a significant proportion of the Tuberculosis (TB) burden of the world. TB diagnosis, treatment, and success are complicated by the chronic nature of the disease as well as additional stressors including financial, psychological, and social hardships, adverse events associated with management, and poor compliance towards anti-tuberculosis medications. METHODS: This is a longitudinal study conducted in the Tuberculosis Units (TUs) of rural field practice areas of the Department of Community Medicine and Family Medicine in a tertiary care hospital in Odisha. 168 diagnosed TB patients from the TUs were enrolled after registration in NTEP and were followed up every month for 6 months or treatment completion. TB patient's cost estimate tool was used to collect data regarding the cost incurred by the patients before and during the diagnosis as well as in the post-diagnosis or treatment period. RESULTS AND CONCLUSION: Out-of-pocket expenditure was calculated as direct, indirect, and total cost in the pre and post-diagnostic phases of the disease. The median pre and post-diagnosis direct, indirect and total costs were ₹ 12,805, ₹ 16,960 and ₹ 31,192, respectively, with almost 62 % of participants spending more than 20 % of their annual income. In this study, 41 % of participants had to stop working for more than 60 days, and 53.1 % faced distress financing due to the disease. Through this study, we found that more than half of rural TB patients still visit private health facilities, and 20 % start anti-TB drugs by purchasing them from private pharmacies, which incur substantial out-of-pocket expenditure. Most participants faced catastrophic costs associated with hospitalisation, lower family income, and a delay in disease diagnosis.


Asunto(s)
Costo de Enfermedad , Gastos en Salud , Población Rural , Tuberculosis , Humanos , India/epidemiología , Estudios Longitudinales , Femenino , Masculino , Adulto , Gastos en Salud/estadística & datos numéricos , Persona de Mediana Edad , Tuberculosis/economía , Tuberculosis/tratamiento farmacológico , Tuberculosis/epidemiología , Estrés Financiero , Antituberculosos/uso terapéutico , Antituberculosos/economía , Adulto Joven
18.
Indian J Tuberc ; 71 Suppl 2: S250-S257, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39370192

RESUMEN

INTRODUCTION: Poor adherence to anti-tuberculosis medication is a major barrier to its global control. Patient adherence to the standard anti-TB therapy (ATT) in developing countries has been estimated to be as low as 40%. Multiple factors influencing adherence to treatment are: Economic and structural factors such as homelessness, unemployment and poverty; patient related factors like ethnicity, gender, age, knowledge about TB, cultural belief systems, mental state etc. AIMS & OBJECTIVES: This study was planned with the aim to study the association between various socio-demographic factors with level of adherence to the daily regimen amongst newly diagnosed pulmonary TB patients at a tertiary care hospital in metropolitan city of Maharashtra. Additionally, we tried to determine the type of non-adherence along with reasons for it. METHOD: ology: An interview based pre-tested and validated questionnaire was developed & used as data collection tool. Total 181 newly diagnosed, FDC naïve, drug sensitive pulmonary TB patients from DOT center of a tertiary care hospital were enrolled & interviewed for sociodemographic, treatment & adherence details. They were followed up at 2nd & 6th month of their treatment, i.e., IP & CP follow up. Their Nikshay portal data & TB treatment cards were accessed for information on treatment adherence. RESULTS: Out of 181 patients, 110 (60.8%) were found to be adherent whereas 71 (39.2%) were found to be non-adherent. Among those non-adherent, 64 (90.9%) had treatment gaps (intermittent missed doses) & 7 (9.9%) showed discontinuation of treatment. Majority of these patients reported personal obligations & starting to feel better as the main reason for non-adherence (p < 0.0001). The sociodemographic factors that had significant impact on level of adherence were patients' age (p = 0.013); level of education (p = 0.035); family size (p = 0.018); family history of TB (p = 0.0001) & current smoking habit (p = 0.025). CONCLUSION: It is evident from the study that socio-demographic factors do have a major impact on patients' levels of adherence to treatment. Family history of TB as well as sputum conversion at end of treatment/CP have been identified as independent risk factors among pulmonary TB patients who are non-adherent to treatment. Thus, ensuring robust availability of DBT & intensive tobacco cessation sessions for all diagnosed patients as well as strengthening system for making prophylaxis available for household & close contacts of patients can help in reducing impact of socio-demographic factors & improving adherence levels. RECOMMENDATIONS: In-patient care option specifically during IP; regular dietary counseling to improve nutrition & help reduce drug side effects & use of alternate adherence technologies like facility-based DOT or Video Observed Therapy (VOT) wherever feasible can help to improve adherence levels for TB patients from all walks of life.


Asunto(s)
Antituberculosos , Cumplimiento de la Medicación , Tuberculosis Pulmonar , Humanos , Tuberculosis Pulmonar/tratamiento farmacológico , Masculino , Femenino , Antituberculosos/uso terapéutico , Antituberculosos/administración & dosificación , Adulto , Cumplimiento de la Medicación/estadística & datos numéricos , Persona de Mediana Edad , Estudios de Seguimiento , India , Adulto Joven , Factores Socioeconómicos , Encuestas y Cuestionarios , Terapia por Observación Directa , Escolaridad , Adolescente , Factores Sociodemográficos , Factores de Edad
19.
BMC Infect Dis ; 24(1): 1140, 2024 Oct 10.
Artículo en Inglés | MEDLINE | ID: mdl-39390402

RESUMEN

Tuberculosis (TB) is a serious infection that can involve any organ system and present in various forms. About one-third of the world's population are carriers of latent TB. Although most cases are from a pulmonary origin, there is a rising prevalence of abdominal TB. Patients with pulmonary or extrapulmonary TB are treated similarly through the use of pharmacological therapy. Nonspecific clinical manifestations of TB have made it difficult for clinicians to diagnose. Peritoneal tuberculosis (PTB) is a serious concern as its symptoms overlap with that of many other chronic conditions, especially in those who are immunocompromised. The lack of highly sensitive and specific testing methods has made early intervention difficult, therefore a high index of suspicion is crucial in the progression of the disease. Here, we present a case of a 71-year-old female with a history of abdominal pain, fever, and weakness. Initial investigation with computed tomography (CT) imaging revealed omental fat stranding that pointed towards peritoneal carcinomatosis (PC) from possible recurrence of her ovarian cancer. Further investigation with a peritoneal biopsy was remarkable for caseating granulomas with fat necrosis confirming extrapulmonary TB. This report highlights a rare case of PTB mimicking PC in an elderly patient who is immunocompromised from the use of long-term corticosteroids who continued to decline after pharmacological treatment of the disease.


Asunto(s)
Neoplasias Peritoneales , Peritonitis Tuberculosa , Humanos , Femenino , Anciano , Peritonitis Tuberculosa/diagnóstico , Peritonitis Tuberculosa/tratamiento farmacológico , Peritonitis Tuberculosa/diagnóstico por imagen , Neoplasias Peritoneales/diagnóstico , Neoplasias Peritoneales/secundario , Neoplasias Peritoneales/tratamiento farmacológico , Neoplasias Peritoneales/diagnóstico por imagen , Diagnóstico Diferencial , Tomografía Computarizada por Rayos X , Antituberculosos/uso terapéutico , Huésped Inmunocomprometido , Carcinoma/diagnóstico
20.
J Assoc Physicians India ; 72(10): 93-95, 2024 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-39390870

RESUMEN

Addison's disease (AD), or primary adrenal insufficiency, was first described by Thomas Addison in patients with adrenal tuberculosis (TB). Over the past several decades, along with the introduction of antituberculous treatment (ATT), the incidence of both has declined. The most common symptoms are nonspecific, leading to delayed diagnosis; patients may first present with a life-threatening crisis. Here, we report a case of AD that, upon further workup, was found to be due to one of the most common infections in India-TB.


Asunto(s)
Enfermedad de Addison , Humanos , Enfermedad de Addison/diagnóstico , Enfermedad de Addison/tratamiento farmacológico , Masculino , Adulto , Antituberculosos/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA